The FDA certainly had a busy December, and this week, we’ll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Olaparib for Patients With Germline BRCA Mutated Metastatic Pancreatic Cancer

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer

FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer

FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer

FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer